See more : Future Vision II Acquisition Corp. (FVN) Income Statement Analysis – Financial Results
Complete financial analysis of NLS Pharmaceutics AG (NLSP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NLS Pharmaceutics AG, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- monoAI technology Co.,Ltd. (5240.T) Income Statement Analysis – Financial Results
- Om Infra Limited (OMINFRAL.NS) Income Statement Analysis – Financial Results
- Nicca Chemical Co.,Ltd. (4463.T) Income Statement Analysis – Financial Results
- Relevant Gold Corp. (RGC.CN) Income Statement Analysis – Financial Results
- Charoong Thai Wire and Cable Public Company Limited (CTW.BK) Income Statement Analysis – Financial Results
NLS Pharmaceutics AG (NLSP)
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 11.41K | 11.41K | 10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -11.41K | -11.41K | -10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.91M | 8.98M | 5.92M | 99.58K | 1.70M | 1.44M | 4.32M |
| General & Administrative | 5.90M | 6.51K | 5.94K | 2.20K | 3.30M | 2.01M | 1.44M |
| Selling & Marketing | 0.00 | 6.49M | 5.93M | 2.20M | 2.49M | 0.00 | 0.00 |
| SG&A | 5.90M | 6.49M | 5.93M | 2.20M | 2.49M | 2.01M | 1.44M |
| Other Expenses | 0.00 | 10.05K | -17.32K | -328.37K | 0.00 | -629.23K | 0.00 |
| Operating Expenses | 11.81M | 15.47M | 11.85M | 2.30M | 4.20M | 3.45M | 5.77M |
| Cost & Expenses | 11.81M | 15.48M | 11.86M | 2.30M | 4.20M | 3.45M | 5.77M |
| Interest Income | 0.00 | 100.87 | 68.13 | 233.70 | 819.71 | 16.04K | 890.40 |
| Interest Expense | 145.15K | 100.87K | 68.13K | 233.70K | 819.71K | 1.07M | 890.40K |
| Depreciation & Amortization | 11.41K | 11.41K | 10.05K | 2.30M | 4.20M | 3.45M | 5.77M |
| EBITDA | -11.80M | -15.47M | -11.85M | 0.00 | -430.40K | -613.20K | -5.77M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.81M | -15.48M | -11.86M | -2.30M | -4.20M | -3.45M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -364.97K | -1.01M | -85.46K | -562.07K | -1.25M | -1.70M | -890.40K |
| Income Before Tax | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.00 | -226.51K | -2.30K | -4.20K | 1.70M | -5.77K |
| Net Income | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| EPS Diluted | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| Weighted Avg Shares Out | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
| Weighted Avg Shares Out (Dil) | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
NLS Pharmaceutics Stock (NLSP) Why The Price Surged Today
The stock price of NLS Pharmaceutics AG (NASDAQ: NLSP) increased by over 80% during intraday trading today. This is why it happened.
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
NLS Pharmaceutics Shares Increase Over 30% Intraday: Why It Happened
The shares of NLS Pharmaceutics Ltd. (NASDAQ:NLSP) increased by over 30% intraday.
Buying Penny Stocks Right Now? 3 to Watch in 2021
Looking to buy penny stocks in 2021? Check these 3 out for your list The post Buying Penny Stocks Right Now?
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
New Strong Sell Stocks for July 30th
AEVA, FTS, GOL, NLSP and PCH have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2021.
Top Penny Stocks to Buy in 2021? 6 To Know About in July
Penny Stocks Are Heating Up Right Now; Here's 6 For Your July Watchlist The post Top Penny Stocks to Buy in 2021? 6 To Know About in July appeared first on Penny Stocks to Buy, Picks, News and Information |...
NLSP Stock Increases Over 15% Pre-Market: Why It Happened
The stock price of NLS Pharmaceutics AG (NASDAQ: NLSP) increased by over 15% pre-market. This is why it happened.
NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
Source: https://incomestatements.info
Category: Stock Reports